FDA approves EMD Serono-Pfizer's Rebif auto-injector

The FDA has approved Rebif Rebidose, a single-use auto-injector prefilled with EMD Serono and Pfizer's ($PFE) interferon beta-1a, for the treatment of relapsing forms of multiple sclerosis. Interferon beta-1a is an established and effective disease-modifying treatment for MS, but some people can struggle with injections, and the resulting drops in compliance mean the treatment is less effective. A simple-to-use, single-use auto-injector as an alternative delivery option could make it easier for patients to self-administer the drug. Rebif Rebidose's approval follows a 12-week Phase IIIb multicenter, open-label, single-arm study, wherein most of the patients found the Rebif Rebidose device easy to use. EMD Serono is the U.S. subsidiary of Merck KGaA of Darmstadt, Germany. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…